The over-the-counter pain medication market size to attain a valuation of by 2034, up from in 2024. The over-the-counter analgesics market is projected to evolve at a CAGR of 4.0% between 2024 and 2034.
Over-the-Counter Pain Medication Solutions for Aging Populations
Customers are looking for better options with fewer side effects due to regulatory bodies' strict analysis and safety standards surrounding prescription painkillers. When taken as prescribed, over-the-counter painkillers are thought to be safer alternatives, which fuels consumer demand for over-the-counter pain medications.
The demographic trend of the senior population is a significant catalyst propelling OTC pain medication market growth. As people get older, they are more prone to chronic pain-causing disorders. That is the reason there is a surging demand for over-the-counter pain medications that are also easily available and reasonably priced.
| Attributes | Details |
|---|---|
| Market Value for 2024 | US$ 23,705.60 million |
| Market Value for 2034 | US$ 35,090.10 million |
| Market CAGR from 2024 to 2034 | 4.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Consumer purchasing behavior is likely to be negatively affected by rising healthcare expenditures, including insurance premiums and prescription drug costs. Sales of over-the-counter painkillers are likely to be hindered by consumers choosing less expensive generic substitutes instead of prescription drugs. Companies ought to keep an eye on trends in healthcare costs and modify their marketing to emphasize the advantages of over-the-counter (OTC) products over prescription ones.
| Attributes | Details |
|---|---|
| Market Value for 2019 | US$ 18,678.80 million |
| Market Value for 2023 | US$ 22,741.60 million |
| Market CAGR from 2019 to 2023 | 4.0% |
The segmented over-the-counter pain medication market analysis is included in the following subsection. Based on comprehensive studies, the acetaminophen sector is leading the drug class category, and the oral segment is commanding the route of administration category.
| Segment | Acetaminophen |
|---|---|
| Share (2024) | 46% |
Due to its non-NSAID status, acetaminophen is prescribed to people who are not able to take standard anti-inflammatory medications. Acetaminophen's market dominance is increased by the steady demand for the drug, which is in line with the expanding trend of self-medication. A greater emphasis on liver safety is encouraging patients and medical professionals to choose acetaminophen as a reliable option. Since it works so well and has so many uses, acetaminophen is a strong contender in the crowded OTC painkiller market.
| Segment | Oral |
|---|---|
| Share (2024) | 44% |
Oral drugs are more widely available and well-known, which helps propel sales of over-the-counter pain medication because customers rely on and trust these reputable manufacturers. Oral medications have traditionally been the target of marketing campaigns and consumer education programs, boosting sales by increasing brand recognition and loyalty. Oral pain medications' ability to treat various illnesses confirms their status as the market leader for over-the-counter pain relievers.
Principal Consultant
The over-the-counter pain medication market can be observed in the subsequent tables, which focus on the leading regions in North America, Europe, and Asia Pacific. A comprehensive evaluation demonstrates that Asia Pacific has enormous market opportunities for over-the-counter pain medications.
Insights into the Asia Pacific Over-the-counter Pain Medication Market
| Countries | CAGR (2024 to 2034) |
|---|---|
| India | 5.4% |
| Thailand | 5.0% |
| Indonesia | 3.7% |
| Malaysia | 3.7% |
In India, the demand for over-the-counter pain relievers is driven by rising healthcare costs and the incidence of chronic pain problems. In India, over-the-counter pain medications and traditional treatments coexist, resulting in a varied market environment. OTC painkillers are more accessible in remote parts of India due to e-commerce sites, fostering the over-the-counter pain medication market growth.
OTC pain relief product demand is rising in Thailand due to changing lifestyles and increased urbanization. Thai customers' frequent need for price and convenience in over-the-counter pain medications supports the popularity of combination formulations and generics.
Consumer choices in Indonesia's over-the-counter pain medication industry are positively impacted by cultural preferences and traditional cures, which promote a blend of modern and herbal products. In Indonesia, smartphone apps and digital health platforms are important resources for consumer education and the promotion of OTC painkillers, surging the sales of over-the-counter pain medications.
The growing demand for over-the-counter painkillers in Malaysia is attributed to rising health consciousness and self-care awareness. In Malaysia, local and multinational pharmaceutical companies compete in the over-the-counter (OTC) pain medication market by providing a variety of medications to meet the needs of different customer segments.
Perspectives on Europe’s Over-the-Counter (OTC) Pain Medication Market Dynamics
| Countries | CAGR (2024 to 2034) |
|---|---|
| United Kingdom | 4.0% |
| Italy | 3.8% |
| France | 3.6% |
| Germany | 3.4% |
| Spain | 2.8% |
Online retail channels are becoming a growing trend in the United Kingdom, providing customers with an easy way to buy over-the-counter pain relief medications and stimulating the industry. The over-the-counter analgesics market is shaped by the increased sports and fitness activities in the United Kingdom, concentrating on goods designed to reduce pain and injuries associated with exercise.
The Italy over-the-counter (OTC) pain medication market is shaped by the cultural emphasis on proactive health measures and wellness, specifically preventative healthcare practices. Homeopathic and natural over-the-counter pain management options are becoming progressively widespread in Italy, indicative of a larger movement towards holistic well-being.
The OTC pain medication industry is influenced by the French government's emphasis on preventative healthcare, which emphasizes lifestyle choices and general well-being. French producers of over-the-counter painkillers take advantage of the growing sway of internet health information by using digital channels for focused advertising.
Through the integration of telemedicine and digital health platforms, Germany is witnessing an increase in technology-driven healthcare solutions, which affects the over-the-counter pain medication industry. Pharmacies are important distribution channels for over-the-counter analgesics and significantly impact customer trust in Germany's healthcare system.
The aging population in Spain raises the demand for over-the-counter pain medications that address illnesses and discomforts associated with aging. To influence market trends, regulatory measures in Spain concentrate on improving consumer education and proper adoption of over-the-counter pain medications.
Growth Prospects in North America Over-the-Counter Analgesic Market
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 3.8% |
| Canada | 4.5% |
The demand for over-the-counter pain medications is escalating due to the rising pain awareness and aging population in the United States. Online shopping is a convenient way for customers to purchase over-the-counter pain drugs, and e-commerce platforms are a key component of the distribution network. OTC pain medications are easily accessible to many consumers due to regulatory support and vast retail availability, promoting over-the-counter (OTC) pain medication market expansion in the United States.
The increasing adoption of combination over-the-counter (OTC) pain medicines in Canada is notable, as they offer holistic pain treatment for various pain conditions while addressing several symptoms. Pharmacy-led programs, such as more pharmacist participation in patient education, boost consumer confidence in selecting effective medications and promote over-the-counter analgesic market expansion.
Vital over-the-counter pain medication vendors control a large portion of the market's competitive landscape, driving innovation and influencing market dynamics. Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., and GlaxoSmithKline plc are prominent over-the-counter pain medication providers.
Use their broad portfolios and global reach to stay at the top of their respective markets. In this competitive over-the-counter pain medication market, Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. all have major roles to play, and each brings distinctive strategies and strengths to the forefront.
These over-the-counter pain medication providers use various strategies, including aggressive marketing campaigns, strategic alliances, and product differentiation, to set themselves apart from the competition and gain market share. To meet consumers' varied demands and preferences, constant attempts are made to improve products' convenience, safety, and efficacy.
Regulatory adherence, brand reputation, and distribution networks are crucial factors impacting the strength of the over-the-counter pain medication market. To sustain a competitive advantage and promote sustainable expansion, businesses allocate significant funds to research and development, quality control, and customer service.
As major over-the-counter pain medication vendors constantly work to accommodate changing customer needs while managing regulatory obstacles and economic realities, the industry thrives on fierce rivalry and innovation.
Notable Advancements and Innovations
| Company | Details |
|---|---|
| Medterra | Medterra's latest offering, the Natural Pain Relief capsules, launched in 2023. These capsules are a clinically validated pain management option that utilizes plant-based components to effectively relieve muscle pain, joint stiffness, and inflammation. They are unique in that they can provide these advantages without the usual unfavorable side effects frequently associated with over-the-counter (OTC) pain treatment options. |
| Ratiopharm | Synofen is a new over-the-counter pain reliever that was introduced in January 2023 by Ratiopharm, a well-known German pharmaceutical firm. This novel drug offers a comprehensive approach to pain management, 200 mg of ibuprofen and 500 mg of paracetamol. This introduction represents a significant development in over-the-counter pain management products by providing a comprehensive and efficient way to reduce discomfort. |
| CV Sciences Inc. | A new range of over-the-counter pain relievers was introduced in January 2022 by CV Sciences Inc., a well-known brand in producing CBD products. The four distinct +PlusCBD discomfort Relief topicals are designed to relieve mild discomfort and are infused with quality hemp-derived CBD. |
| European Commission | The European Commission launched the European Research Area (ERA) Corona platform in May 2020, which included information on cutting-edge COVID-19 solutions. According to the European Medicines Agency, non-steroidal anti-inflammatories (NSAIDs), such as ibuprofen and paracetamol, ought to be used sparingly to treat moderate COVID-19 symptoms. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The over-the-counter (OTC) pain medication market to secure a valuation of US$ 23,705.60 million in 2024.
The over-the-counter (OTC) analgesics market is estimated to reach US$ 35,090.10 million by 2034.
Through 2034, the over-the-counter analgesics market is likely to exhibit at a 4.0% CAGR.
From 2019 to 2023, the OTC pain medication market exhibited an HCAGR of 4.0%.
The acetaminophen sector is scheduled to possess a share of 46.0% in 2024.
A 44% market share is expected for the oral sector in 2024.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2024 to 2034
5.3.1. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.3.2. Local Anaesthetics
5.3.3. Acetaminophen
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024 to 2034
6.3.1. Oral Over-the-Counter Pain Medication
6.3.2. Topical Over-the-Counter Pain Medication
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2024 to 2034
7.3.1. Tablets
7.3.2. Capsules
7.3.3. Creams
7.3.4. Gels
7.3.5. Others
7.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Dosage Form, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034
8.3.1. Hospital Pharmacies
8.3.2. Drug Stores
8.3.3. Retail Stores
8.3.4. E-Commerce
8.3.5. Others
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Dosage Form
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Dosage Form
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Dosage Form
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Dosage Form
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Dosage Form
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Dosage Form
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Dosage Form
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Dosage Form
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Dosage Form
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Dosage Form
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Dosage Form
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Dosage Form
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Route of Administration
16.2.4. By Dosage Form
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Dosage Form
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Market Share Analysis, 2023
17.1.1.1. By Drug Class
17.1.1.2. By Route of Administration
17.1.1.3. By Dosage Form
17.1.1.4. By Distribution Channel
17.2. Canada
17.2.1. Market Share Analysis, 2023
17.2.1.1. By Drug Class
17.2.1.2. By Route of Administration
17.2.1.3. By Dosage Form
17.2.1.4. By Distribution Channel
17.3. Brazil
17.3.1. Market Share Analysis, 2023
17.3.1.1. By Drug Class
17.3.1.2. By Route of Administration
17.3.1.3. By Dosage Form
17.3.1.4. By Distribution Channel
17.4. Mexico
17.4.1. Market Share Analysis, 2023
17.4.1.1. By Drug Class
17.4.1.2. By Route of Administration
17.4.1.3. By Dosage Form
17.4.1.4. By Distribution Channel
17.5. Germany
17.5.1. Market Share Analysis, 2023
17.5.1.1. By Drug Class
17.5.1.2. By Route of Administration
17.5.1.3. By Dosage Form
17.5.1.4. By Distribution Channel
17.6. UK
17.6.1. Market Share Analysis, 2023
17.6.1.1. By Drug Class
17.6.1.2. By Route of Administration
17.6.1.3. By Dosage Form
17.6.1.4. By Distribution Channel
17.7. France
17.7.1. Market Share Analysis, 2023
17.7.1.1. By Drug Class
17.7.1.2. By Route of Administration
17.7.1.3. By Dosage Form
17.7.1.4. By Distribution Channel
17.8. Spain
17.8.1. Market Share Analysis, 2023
17.8.1.1. By Drug Class
17.8.1.2. By Route of Administration
17.8.1.3. By Dosage Form
17.8.1.4. By Distribution Channel
17.9. Italy
17.9.1. Market Share Analysis, 2023
17.9.1.1. By Drug Class
17.9.1.2. By Route of Administration
17.9.1.3. By Dosage Form
17.9.1.4. By Distribution Channel
17.10. Poland
17.10.1. Market Share Analysis, 2023
17.10.1.1. By Drug Class
17.10.1.2. By Route of Administration
17.10.1.3. By Dosage Form
17.10.1.4. By Distribution Channel
17.11. Russia
17.11.1. Market Share Analysis, 2023
17.11.1.1. By Drug Class
17.11.1.2. By Route of Administration
17.11.1.3. By Dosage Form
17.11.1.4. By Distribution Channel
17.12. Czech Republic
17.12.1. Market Share Analysis, 2023
17.12.1.1. By Drug Class
17.12.1.2. By Route of Administration
17.12.1.3. By Dosage Form
17.12.1.4. By Distribution Channel
17.13. Romania
17.13.1. Market Share Analysis, 2023
17.13.1.1. By Drug Class
17.13.1.2. By Route of Administration
17.13.1.3. By Dosage Form
17.13.1.4. By Distribution Channel
17.14. India
17.14.1. Market Share Analysis, 2023
17.14.1.1. By Drug Class
17.14.1.2. By Route of Administration
17.14.1.3. By Dosage Form
17.14.1.4. By Distribution Channel
17.15. Bangladesh
17.15.1. Market Share Analysis, 2023
17.15.1.1. By Drug Class
17.15.1.2. By Route of Administration
17.15.1.3. By Dosage Form
17.15.1.4. By Distribution Channel
17.16. Australia
17.16.1. Market Share Analysis, 2023
17.16.1.1. By Drug Class
17.16.1.2. By Route of Administration
17.16.1.3. By Dosage Form
17.16.1.4. By Distribution Channel
17.17. New Zealand
17.17.1. Market Share Analysis, 2023
17.17.1.1. By Drug Class
17.17.1.2. By Route of Administration
17.17.1.3. By Dosage Form
17.17.1.4. By Distribution Channel
17.18. China
17.18.1. Market Share Analysis, 2023
17.18.1.1. By Drug Class
17.18.1.2. By Route of Administration
17.18.1.3. By Dosage Form
17.18.1.4. By Distribution Channel
17.19. Japan
17.19.1. Market Share Analysis, 2023
17.19.1.1. By Drug Class
17.19.1.2. By Route of Administration
17.19.1.3. By Dosage Form
17.19.1.4. By Distribution Channel
17.20. South Korea
17.20.1. Market Share Analysis, 2023
17.20.1.1. By Drug Class
17.20.1.2. By Route of Administration
17.20.1.3. By Dosage Form
17.20.1.4. By Distribution Channel
17.21. GCC Countries
17.21.1. Market Share Analysis, 2023
17.21.1.1. By Drug Class
17.21.1.2. By Route of Administration
17.21.1.3. By Dosage Form
17.21.1.4. By Distribution Channel
17.22. South Africa
17.22.1. Market Share Analysis, 2023
17.22.1.1. By Drug Class
17.22.1.2. By Route of Administration
17.22.1.3. By Dosage Form
17.22.1.4. By Distribution Channel
17.23. Israel
17.23.1. Market Share Analysis, 2023
17.23.1.1. By Drug Class
17.23.1.2. By Route of Administration
17.23.1.3. By Dosage Form
17.23.1.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Route of Administration
18.3.4. By Dosage Form
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Pfizer Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Johnson & Johnson Services Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Bayer AG
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Sanofi S.A.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. GlaxoSmithKline plc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Bristol-Myers Squibb Company
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Teva Pharmaceutical Industries Ltd.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Mylan N.V.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Merck & Co.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Cardinal Health Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Over-the-Counter Pain Medication Market
